<DOC>
	<DOCNO>NCT01747707</DOCNO>
	<brief_summary>The combination Cisplatin S-1 ( CS ) achieve response rate approximately 45 % PFS around 6 month overall survival time 13 month Japanese Chinese gastric patient . It remain unclear whether addition docetaxel CS would enhance efficacy dose DCF ( docetaxel , cisplatin 5-fluorouracil ) . This single center , phase II clinical trial evaluate efficacy docetaxel , cisplatin S-1 ( DCS ) first line chemotherapy patient advance gastric gastroesophageal junction cancer .</brief_summary>
	<brief_title>Cisplatin , Docetaxel S-1 Advanced Gastric Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>This single arm trial . All Patients receive 6 cycle triple chemotherapy docetaxel , cisplatin S-1 . Given severe toxicity DCF regimen , total dose docetaxel cisplatin reduce 60mg/m2 . For patient CR/PR/SD disease 6 cycle chemotherapy , maintenance therapy S-1 recommend . Antitumor activity evaluate every two cycle accord RECIST1.1 .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm unresectable advanced gastric gastroesophageal junction cancer ; No previous chemotherapy radiation advance disease except palliative radiation local pain control ; At least one evaluable lesion per RECIST ( Response Evaluation Criteria Solid Tumors ) 1.1 ; ECOG ( Eastern Cooperative Oncology Group ) performance status 01 ; Recovery toxicities previous therapy ; Adequate bone marrow organ function . Hb≥8 G/L ; Absolute neutrophil ≥ 2.0 G/L ; PLT ≥100 G/L ; ALT/AST ≤1.5 ULN ≤5ULN liver metastasis ; TBIL ≤1.5 ULN ; Cr≤1.0 ULN ; Life expectancy ≥3 month ; For men woman childbearing potential , agree take effective contraceptive method birth control sign informed consent 3 month last study drug administration ; Signed informed consent . Pathology type adenocarcinoma , squamous cell carcinoma ; Previous treatment taxanes , cisplatin S1 ; Relapse within 6 month end adjuvant chemotherapy ; Known brain metastasis ; Complete incomplete intestinal obstruction uncontrolled gastrointestinal bleeding ; Known deficiency DPD enzyme ; Kown HIV infecton drug addiction ; Any acute chronic medical psychiatric condition would make patient inappropriate entry trial judgement investigator ; Myocardial infarction within 6 month prior entry trial ; Known history allergic reaction taxanes platinum ; Pregnant breast feed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>gastroesophageal junction cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>S-1</keyword>
</DOC>